Friday, July 12, 2024

A Powerful Memoir - Between Two Kingdoms

The first time I read the writings of  Suleika Jaouad was in her the NY Times column  "Life Interrupted" . She wrote about her leukemia diagnosis and treatments.  In 2022, I shared in this blog a piece Suleika wrote for Nancy's List ( https://nancyslist.org/). That post mentioned her best selling memoir, Between Two Kingdoms , A Memoir of a Life Interrupted.  Back then I added it to my Goodreads "Want to Read" list.

A few weeks ago while browsing a bookstore in Princeton, I saw the book, bought it and started reading it.

In the first few chapters I got to know more about Suleika's family and background. She attended Princeton University, right across the street from the Labyrinth bookstore where I purchased her book. As I read further along I started to dog ear the pages. I tend to do that with books I own so I can come back and reread or share the words. As you can see, I frequently dog eared pages in this book. 

 

Suleika's story as a young cancer patient and survivor is a powerful one. She found the perfect words to describe how she felt both physically and emotionally from diagnosis , through the various treatments and as a survivor. We are thrown into a system we know nothing about so we try to learn as much as we can. We are fatigued from treatments yet we want to still "do" things.   I remember feeling how life went on for others while I couldn't get out of bed. Or that others were annoyed over someone cutting the line at the food store while I wished I could get out there to the food store. Suleika stated is as - " The world is moving forward and I am stuck." So many times as I read the book I thought to myself - " I felt that way" even though my diagnosis was different and I was diagnosed at an older age. 

" To be a patient is to relinquish control- to your medical team and their decisions, to your body and its unscheduled breakdowns. Caregivers have a similar fate." The way in which Suleika described how her diagnosis, treatment and survivorship  affected her mother, father, brother (who provided the bone marrow for her transplant) and boyfriend was especially poignant. We survivors experience the disease, tests, treatments alone - yet our family is equally affected both emotionally and physically.    

Suleika described feelings of loss - facing infertility due to chemotherapy and a bone marrow transplant. She shared the decision and the process to harvest her eggs. She was like so many young women diagnosed with ovarian cancer I have spoke who face infertility.

Especially moving was Suleika's description of the relationships that developed with other young adult  patients, in particular those who died because of their disease. " I think of how the Taj (MAHAL) embodies both love and grief. So did my friendship with Melissa . In life, I'm realizing, you don't get one without the other. "  I understand that so well with the loss of friendships that developed only because we were Teal sisters. I still miss and think about Rita Kay, Carole, Pamela, and so many more.

Suleika faced what so many of cancer patients do regarding being told we are NED ( No Evidence of Disease) and the fear of recurrence.  " The nagging voice in my head that whispered: Don't get too comfortable because one day I'm coming back".

I loved how Suleika learned to drive and took a cross country trip with her dog, Oscar,  to visit strangers who wrote her after reading her NYT column. I couldn't stop reading about each stop and the people - planned and unplanned - she met along the way . "May I be awake enough to notice when love appears and bold enough to pursue it withoug knowing where it will lead." 

As I read Suleika's website I learned she began painting while in the hospital and continues to paint. I started painting too when I in chemotherapy. She is having an art exhibit at the ART yard June 22 - September 22, 2024 in Frenchtown NJ. I regret having waited so long to read this book but I will make a point of going to see her art work. 

 This book  is a keeper and I highly recommend it. 

Thank you Suleika Jaouad for sharing your experience with all of us.

Dee

Every Day is a Blessing! 

Friday, June 28, 2024

Some Thoughts on Quality of Life , Patient Reported Outcomes and Clinical Trials

A few days ago @DrYukselUrun shared on X the ORR ( objective response Rate) and CRR (Complete Response Rate and OS (overall survival) for the  Phase 3 CLEAR trial ( combo of Lenvatinib and Pembrolizumab in advanced renal cell carcinoma).  

 In response,  @StrijbosMichiel posted "Most impressive results from the CLEAR trial: the percentage of patients that have to endure grade 3-4 toxicities....82.3% in the 2021 NEJM publication. Yes you live longer....but at a very very hefty price. "  

Deb Maskens (@DebMaskens) a kidney cancer patient advocate posted: "Please do not post Efficacy numbers without posting what is equally important to patients: Quality of Life! Not just how long we live, but HOW we live. TY" (my emphasis)

What followed was an interesting discussion about QOL when testing new treatments and how they are measured and reported.  What is tolerable for one patient may not be tolerable for another. The fatigue one patient experiences may mean they feel tired for another it may mean they are unable to move out of bed or stand to take a shower.  Trials will report the AE's (Adverse Effects) as recorded by the clinicians and investigators or another person involved in the study. Occasionally patient reported outcomes (PROs) are included as part of the trial.  At oncology meetings there is usually a slide reporting the % of patients enrolled in the trial who experienced AE's from grades 1-4, but the focus when presenting the data is usually on the ORR, PFS or OS.  

It is important that patient reported outcomes become a standard part of the clinical trial process in oncology. The FDA issues a Draft Guidance on Core Patient-Reported Outcomes (PRO) in Cancer Clinical Trials in June 2021.  The guidance includes various tools that can be used to measure patient reported outcomes in the areas of disease related symptoms, systemic adverse events, overall side effect measures , physical function and role functions. It also shows the frequency at which those measures shoe be recorded. The FDA considers PRO's( Clinical Outcome Assessments)  as part of the COA's of a trial (https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcome-assessments). 

I've been thinking about the tools to measure PROs. There is a specific one for ovarian cancer called FACT-O (Functional Assessment of Cancer Therapy – Ovarian (FACT-O). The Assessment covers physical well-being, social/family well-being, emotional well-Being, functional well-being. Patients are asked to respond to statements that have been found to be important by others diagnosed with cancer with one of 5 responses from "not at all" to "very much". What about those issues not listed in the items others found important. There are vision issues with some anti-body drug conjugates now used to treat ovarian cancer but vision is not listed. Others including myself have had dental/ mouth issues during treatment which affect QOL and may fall under other categories but dental issues are not specifically mentioned. There is no space on the questionnaire to enter concerns that are not listed.  I understand it is difficult to capture all of the patient experience in a single questionnaire. 

At the recent ASCO 24 Annual Meeting there were multiple sessions and a keynote speech about artificial intelligence (AI). Can we use AI to read text from patients for example in a treatment diary or in an open ended question on a QOL form? Could those open ended responses be read by the study team in real time - not just for study analysis- so they can be responded to quickly?  How difficult would it be to implement that analysis in all clinical trials in ovarian cancer and other cancers going forward? I don't have the an answer for these questions but I am sure their are other experts who could provide some information. I also would like to see the conclusion slide of each presentation at oncology meetings include those QOL measurements and not a simple statement that there are " no new safety signals" . What were the old signals? 

We have work ahead but patient advocates, the FDA, Pharmaceutical companies and clinicians can work together to insure the patient experience and voice is recorded and used when considering approving treatments.

I'd love to hear from those in AI about the feasibility of implementing AI analyzed textual PROs or those with other ideas on how we can advocate for a greater use of PROs.

Dee

Every Day is a Blessing !

Tuesday, June 11, 2024

An Oncology Equity Summit and #ASCO24 Connections

On Monday June 3, 2024,  I had the opportunity to attend the Pfizer Oncology Health Care Equity Summit: Models for Collaboration and Community Action by Conquer Cancer's EveryGrant®. 

After being welcomed by Dr Katherine Reeder-Hayes, we heard from Dr Aida Habtezion, Chief Medical Officer of Pfizer. After reviewing the representation by race and ethnicity in clinical trials in the US, Dr Habtezion highlighted Pfizers committment to health equity in oncology. 


 

Next, a panel of presenters including advocate Sharon Rivera-Sanchez, shared their research and experience reaching underrepresented patients. 

Brian Rivers, PhD, MPH (Morehouse School of Medicine) spoke on the Deep South Community Health Advocates Network . The Network recruits and trains lay advocates/navigators as community health workers to disseminate cancer information on risk reduction, screening, survivorship and clinical trial participation. He also spoke on a project to improve access to primary care and promote education and preventive screenings for prostate cancer among rural African American men.

Shoshana Rosenberg, ScD, MPH (Weill Cornell Medical College) spoke on the unmet psychosocial needs among adults with metastatic breast cancer in New York City. She described the intervention RAISE,which uses an employment screening tool to assist  with the employment challenges experienced by metastatic  breast cancer patients treated at NYP-Weill Cornell Medicine (Manhattan) and Brooklyn Methodist Hospital. 

Kamran Ansari, MS Pfizer Oncology division spoke on Pfizer's approach to clinical trial diversity

Sharon Rivera-Sanchez, patient advocate and founder of Trials of Color spoke on the barriers to participation in clinical trials such as logistic and financial barriers, lack of awareness of trials, eligibility criteria, mistrust and the complexity of clinical trial platforms. Solutions include education, building relationships, simplifying enrollment, inclusive eligibility, and child care support. Her final remark needs highlighting!

Kenneth W. Merrell, MD, Medical Director Global Bridges, shared  the mission of Global Bridges to mobilize a global network of healthcare professionals and organizations dedicated to advancing effective diagnosis and treatment through medical education. The progam has training 50,000 Health Care Providers in 85 countries. They have provided 17 grants in oncology in the 2024-2026 cycle in Africa. 

Yanin Chavarri Guerra, MD, MSc Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubriran , Mexico spoke on the social determinants of health and disparities in cancer care for patients with metastatic breast cancer in Mexico. Patients were recruited from 3 hospitals. The barriers related to social determinants of health in patients with metastatic breast cancer may be addressed by system-level interventions.

Salvatore Alesci, MD, PhD, National Minority Quality Forum (NMQF) shared the NMQF vision to achieve a just and fair American health system that insures equitable access to optimal care. 

Andrew E. Chapman, DO, FACP, FCPP Director of the Sidney Kimmel Cancer Center at Jefferson concluded the panel discussion . He discussed how the ACES model ( Access and Care Engagement Support) can transform cancer care at the cancer center's main and regional sites.

One of the best parts of attending ASCO are the connections and reconnections I make with other advocates and researchers. This year I was able to catch a few of those connections in photos. Great times with  Barbara, Helen, Stacey, Stephanie, Ting Ting, and Annie.  


But there were also the important connections with clinicians and researchers I have worked with through the years on developing trials, the #gyncsm community, ASCO or the NCI and Cancer Hope Network. It was wonderful meeting Drs Markham and Samantha Schrager (Cancer Hope Network),  Cervical Cancer Advocate Linda Ryan and Dr Kohn, as well as Dr Dellinger, Lou, and Dizon.



I also got to reconnect with Dr Ophira Ginsburg at the President's Reception. We first met at the ASCO Annual Meeting in 2015. 

 

This post completes my reporting from #ASCO24. There will be a bit of a break posting on this blog and  from advocacy over the summer but September - Gyn Cancer Awareness month is right around the corner. 

Dee
Every Day is a Blessing! I was blessed to have not only attended but presented at ASCO this year. 

Friday, June 7, 2024

Gyn Cancer Poster Session - Ovarian Cancer posters #ASCO24

Monday was Gyn Cancer Poster day at #ASCO24.  

Here are a few posters along with their study conclusions that I found most interesting this year. 

Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer. #5544
"The present tumor-informed dPCR SV fingerprint ctDNA approach demonstrated feasibility with remarkably high detection rates pre- and postoperatively. Postoperative ctDNA levels differed substantially based on postoperative tumor residuals. These findings suggest that this personalized approach could be used to develop a dPCR SV detection assay and may have clinical utility for postoperative MRD evaluation in patients with primary advanced HGSOC."  
Through the years there has been a lot of talk regarding detecting circulating tumor DNA in the blood of patients. This study showed ctDNA could be used  as a marker in ovarian cancer .


Differences in physical and emotional distress amongst patients undergoing neoadjuvant chemotherapy versus surgery for advanced ovarian cancer: Patient-reported outcomes at diagnosis.   #5546
"Advanced OC patients have high psychosocial needs, with NACT patients reporting severe perceived symptoms on PRO measures. The PSS-10 may be a valuable screening tool for patients undergoing NACT to prioritize supportive care services."

Use of cell-free DNA from ascites to identify variants and tumour evolution in a cohort of patients with advanced ovarian cancer. #5547
This work "demonstrated the reliability of using cfDNA from ascites for molecular profiling, allowing a liquid biopsy of ovarian cancer when tumor tissue access may be restricted. This approach improves accessibility of tumour material, allowing capture of clinically actionable mutations prior to surgery or upon recurrence, following tumour evolution."
There is a difference between cfDNA and ctDNA- "The ctDNA is the fraction of cfDNA that originates from tumor cells, which comes from three sources: apoptosis, necrosis, and active secretion. While ctDNA can come from apoptosis with fragment lengths similar to healthy patients, ctDNA is more fragmented or shorter than cfDNA [20,32,33]. "  Source : NIH

Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. #5548
"Cisplatin in combination with gemcitabine demonstrates activity regardless of platinum sensitivity status in patients with recurrent ovarian cancer. However, longer platinum-free interval is associated with improved response to this therapy".

 Evaluation of a novel extracellular vesicle (EV) based ovarian cancer (OC) screening test in asymptomatic postmenopausal women. #5553
"The OC Test is capable of highly sensitive and specific detection of HGSC in asymptomatic postmenopausal women one year prior to Dx and can detect HGSC up to three years prior to Dx with superior sensitivity and specificity compared to CA125." 
Finding a screening test for ovarian cancer is important.  This is a different approach looking at extracellular vesicles. " Extracellular vesicles (EVs) are generated and released by cells as part of various physiological and pathological processes, including the progression of ovarian cancer. "Source Science Direct
 

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings? #5563
"This real world study provides support for findings from ICON7 and GOG-0218, suggesting that the benefit of adding bev to first line chemotherapy may be limited to patients with high-risk clinical factors ( Stage IV disease or stage III disease with visible residual disease or no evidence of surgery). "

 
Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer. #5574
"We observed positive associations between health tracker physical activity data and pt-reported QOL. Stronger associations were observed in younger pts. Interventions aimed at increasing physical activity may have broader quality of life benefits for individuals with ovarian cancer." 
When I was first diagnosed I was told to rest during chemotherapy treatment. When I recurred a few years later I was told to try to walk each day. I'm glad that theren is now data saying that exercise has QOL benefits.

 
Artificial intelligence to predict homologous recombination deficiency in ovarian cancer from whole-slide histopathological images. #5578
"By harnessing the power of deep neural networks (DNN), we provide a rapid and scalable solution for HRD prediction, circumventing the limitations of traditional molecular assays. Successful integration of this deep learning model into routine pathology workflows could significantly enhance diagnostic efficiency, reduce the turnaround time and financial cost compared with molecular assay. " 
There were a number of talks at ASCO related to the use of AI. HRD is a marker used to manage ovarian cancer patient treatments.

 
Germline genetic profiles of women with ovarian malignancies: A Myriad Collaborative Research Registry study #5585
"Based on this large registry, our data showed that over 15% of patients with ovarian malignancies have mutations in BRCA (12.5%) or Lynch genes (2.6%) with varying prevalence by race, age, and tumor site. Noted disparities indicate the importance of universal testing in patients with epithelial ovarian malignancies."  
I knew that Lynch syndrome was associated with endometrial cancer but I did not associate ovarian cancer with Lynch sydrome. 

 
Which posters caught your eye? Share them in a comment below.
Tomorrow,  I will post about a equity symposium I attended as well as the  connections and reconnections I made at the annual meeting.
Dee
Every Day is a Blessing!

Thursday, June 6, 2024

Sunday at #ASCO24 Oral Abstracts and Rare Gyn Cancers

My meeting days all started with picking up a bite to eat in the Patient Lounge. The lounge was a great place to meet up with other advocates from around the world, relax is comfy chairs  and pick up a bite to eat at breakfast or lunch. 

Sunday started with the Gyn Cancer Oral Abstract Session followed by an afternoon of meeting with clinicians I am working with as well as learning about Patient Story .

Clear Cell OC

 Recurrent OC no additional benefits from adding Atezolizumab

 Endometrial Cancer 

Pharma support of trials 

When Bad News Comes Through the Portal ... Education Session

Exploring the Uncommon: What's New in Rare Gyn Cancers  - Low grade serous , Melanoma of the gyn tract and neuroendocrine carcinomas of the cervix

Obesity and Endometrial Cancer

Cervical Cancer

Metastatic disease clinical trials 

 Tomorrow I'll review a few of the posters as well as a round-up of the connections I made. 


Dee

Every Day is a Blessing!

Wednesday, June 5, 2024

Saturday at #ASCO24 - Science, Opening Session and My Social Media Panel Presentation

Over the next few days I will share my experience at #ASCO24 , the science I learned , amazing people I spoke to and of course my presentation on social media. 

Late in the day on Friday,  I finally got to McCormick Place. The traffic from the airport was dreadful but I arrived in time to pick up my badge from the Faculty Lounge. Then I headed to my favorite sushi place - Nui Sushi for dinner.

Rapid Oral Abstract Session Highlights. (I missed some sessions as I had scheduled a time to practice my presentation. )

Ovarian Cancer: AXL expression can be used as a biomarker in OC. Those with high AXL expression had improved PFS and OS when treated with Bateraxcept in combo with taxol.

Ovarian Cancer: Use of suvemcitug, an anti-VEGF drug with chemo,  met PFS goal 5.49 months vs placebo at 2.73 months.

Ovarian , Fallopian, Peritoneal Cancers: Oral cyclophosphamide can be used together- Objective response rate 40%

President's Speech and Invited Speakers

Dr Lynn Schuchter,President of ASCO, inspiring speech.  

Jonathan Carlson, Microsoft Health Futures, spoke on AI use in medicine

Abraham Verghese , Stanford spoke next relating to the meeting theme Art and Science

Clinical Science Symposium Novel combinations across the gyn cancer spectrum

Ovarian Cancer combinations:

Cervical Cancer mTOR inhibitors

Ovarian Cancer - overcoming PARP resistance , HRD status did not impact response

A review of combos:

Endometrial cancers CTK4 inhibitors 

Future Endometrial Cancer work

I finished the day participating in a panel with Dr Gil Morgan and Dr Gil Lopez  on Harnessing the Power of Social Media. What an honor! Below are a few tweets from the audience. Dr Morgan spoke on using social media to improve global oncology and the The OncoAlert Consortium. Dr Lopez spoke on using social media to advance research and professional development. I spoke on social media to educate patients with cancer and clinicians.


Check back to read posts highlighting Sunday's Session and the connections I made at ASCO with researchers, clinicians and other advocates. 

Dee

Every Day is a Blessing!

Friday, May 24, 2024

Gynecologic Cancer Sessions at #ASCO24

 

From May 31st to June 4th the ASCO Annual Meeting will be held in Chicago. The theme this year is The Art and Science of Cancer Care: From Comfort to Cure. This meeting brings to McCormick Place more than 30,000 oncologists, researchers, allied science professionals and patient advocates from around the world.

I will be attending in person and posting/tweeting to X from various sessions using the #gyncsm and #ASCO24 hashtags.

The complete program may be found at  https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2024-05/AM24-Program.pdf )

Below  is a list of the Gynecologic Cancer sessions ( Scientific & Education).

Saturday June 1, 2024 
8am Rapid Oral Abstract Session  E-451   
can't wait to hear more about:
Abstract 5518: Relationship of cancer stem cell
functional assay and objective response rate of patients
with recurrent platinum-resistant ovarian cancer in a
randomized trial.
Abstract 5520: Secondary cytoreduction followed by
chemotherapy versus chemotherapy alone in platinum-
sensitive relapsed ovarian cancer (SOC-1): A final overall
survival analysis of a multicenter, open-label, randomized,
phase 3 trial.


1:15pm Clinical Science Symposium -  Stronger Together: Novel Combinations Across the
Gynecologic Cancer Spectrum , E-451 
can't wait to hear more about:
Abstract 5509, A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patient with advanced solid tumors: Cervical cancer cohort.
Abstract 5510, Combination ATR and PARP Inhibitor(CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial
ovarian cancer (cohort A).
Abstract 5511, A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or
recurrent endometrial cancer.


Sunday June 2, 2024 
8:00am Oral Abstracts Hall D-2
  can't wait to hear more about:
Abstract LBA5500: Final results of BrUOG 354: A
randomized phase II trial of nivolumab alone or in
combination with ipilimumab for people with ovarian and
other extra-renal clear cell carcinomas.
Abstract LBA5501: Atezolizumab versus placebo in
combination with bevacizumab and non-platinum-based
chemotherapy in recurrent ovarian cancer: Final overall
and progression-free survival results from the AGO-OVAR
2.29/ENGOT-ov34 study.
Abstract 5502: Vibostolimab coformulated with
pembrolizumab (vibo/pembro) for previously treated
advanced mismatch repair–deficient (dMMR) endometrial
cancer: Results from cohort B1 of the phase 2
KEYVIBE-005 study.
Abstract 5503: Trends in phase 3 gynecological
clinical trials of targeted therapies: Study oversight and
pharmaceutical involvement in the past 12 years.
Abstract 5507: Endometrial cancer and obesity trends in
the United States in the 21st century.
First Author: Alex Andrea Francoeur, MD
 
Case Based Panel Optimizing the Therapy Sequence in High-risk Endometrial Cancer - E451a (11:30am -12:30pm CT  )  
Molecular analysis, patient guidance and clinical trial perspective for Endometrial cancer will be discussed.
 
Education Session - Exploring the Uncommon: What's New in Rare Gyn Cancers  
Low-Grade Serous Ovarian Cancer, Melanoma of the Gynecologic Tract, and Neuroendocrine Gynecologic Cancer will be discussed. 

Monday June 3 ,2024
9am Poster Session Hall A 
Posters by Topic
Biologic Correlates: Board(s) 392-396
Cervical Cancer: Board(s) 397-413, 492a-493b
Ovarian Cancer: Board(s) 414-458, 494a-500b
Uterine Cancer: Board(s) 459-488, 501a-503a
Other Gynecologic Cancer: Board(s) 489-491, 503b

Poster sessions provide the opportunity to speak directly to researchers about their research results and to learn about early phase research.  With well over 100 posters in the gyn cancer category,  I will concentrate on ovarian cancer posters. Here are a few that piqued my interest.
 
Abstract TPS5635: A randomized, multicenter, open-
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #396
Abstract 5544: Tumor-informed ctDNA as an objective
marker for postoperative residual disease in epithelial
ovarian cancer. #415
Abstract 5546: Differences in physical and emotional
distress amongst patients undergoing neoadjuvant
chemotherapy versus surgery for advanced ovarian
cancer: Patient-reported outcomes at diagnosis. #417
Abstract 5547: Use of cell-free DNA from ascites to
identify variants and tumour evolution in a cohort of
patients with advanced ovarian cancer #418
Abstract 5551: The efficacy and safety of RC88 in
patients with ovarian cancer, non-squamous-non-small-
cell lung-carcinoma and cervical cancer: Results from a
first-in-human phase 1/2  #422
Abstract 5553: Evaluation of a novel extracellular
vesicle (EV) based ovarian cancer (OC) screening test in
asymptomatic postmenopausal women #424
Abstract 5563: The BEV1L study: Do real-world
outcomes associated with the addition of bevacizumab
to first-line chemotherapy in patients with ovarian cancer
reinforce clinical trial findings? #434
Abstract 5573: Feasibility of using the handheld MasSpec
pen technology for intraoperative identification of ovarian
cancer during tumor reductive surgery. #444
Abstract 5578: Artificial intelligence to predict
homologous recombination deficiency in ovarian cancer
from whole-slide histopathological images. #449
Abstract 5585: Germline genetic profiles of women with
ovarian malignancies: A Myriad Collaborative Research
Registry study. #456
Abstract TPS5625: REJOICE-Ovarian01: A phase 2/3
study of raludotatug deruxtecan (R-DXd) in patients with
platinum-resistant ovarian cancer (OVC). #494a
Abstract TPS5635: A randomized, multicenter, open-
label phase III trial of hyperthermic intraperitoneal
chemotherapy in platinum-resistant recurrent ovarian
cancer (KOV-HIPEC-02). #499a


1:15-2:30pm  Education Session:  State of the Art in Gyn Cancer :New Drugs and Companion Diagnostics S 100a   
Immunotherapy, Anti-body drug conjugates and PARP inhibitors will be discussed

3:00-4:15 pm Educations Session: Controversies in the Surgical Management of Gyn Cancer :Balancing the Decision to Operate or Hesitate E450b 
Challenges in gynecologic cancer Surgery, minimally Invasive for fertility-sparing Treatment , and the timing of debulking surgery will be discussed.


Although not specific to gyn cancers, this session on June 3rd is another one I will try to add to my schedule or watch after the meeting.
9:45 AM-11:00 AM Education Session
Solving Decades of Drug Shortages in Oncology: What, Who,
and When?
Location: S100a 


Lastly, In addition to sharing on X presenations from the meeting I will be presenting during the Harnessing the Power of Social Media: Elevating Global Oncology Practice, Research, and Education education session on June 1, 2024 (3-4pm CT) . The topic of my presentation is Social Media as an Educational Tool for Patients and Clinicians. I am so excited that I will get to meet Drs Gil Morgan  and Gilberto Lopez, the other panelist in person . I have followed them for years on Twitter and respect the work they have done on social media.  I hope to see you in room S402!

 I look forward to taking a stroll through the Exhibit hall and  spending time in the Patient Advocate Lounge meeting with other advocates.  I want to give a special shout out to Jill Feldman, Lung Cancer Patient and Advocate on her Patient Advocate Award!   Congratulations, Jill !

If you are attending ASCO which sessions are on your "can't miss" list? 

See you in Chicago!
 
Dee
Every Day is a Blessing